These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10450979)

  • 1. Synthesis of an array of potential matrix metalloproteinase inhibitors using a sequence of polymer-supported reagents.
    Caldarelli M; Habermann J; Ley SV
    Bioorg Med Chem Lett; 1999 Jul; 9(14):2049-52. PubMed ID: 10450979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benzodiazepine inhibitors of the MMPs and TACE.
    Nelson FC; Delos Santos E; Levin JI; Chen JM; Skotnicki JS; DiJoseph JF; Sharr MA; Sung A; Killar LM; Cowling R; Jin G; Roth CE; Albright JD
    Bioorg Med Chem Lett; 2002 Oct; 12(20):2867-70. PubMed ID: 12270165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.
    Jacobson IC; Reddy PG; Wasserman ZR; Hardman KD; Covington MB; Arner EC; Copeland RA; Decicco CP; Magolda RL
    Bioorg Med Chem Lett; 1998 Apr; 8(7):837-42. PubMed ID: 9871551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.
    Hanessian S; Bouzbouz S; Boudon A; Tucker GC; Peyroulan D
    Bioorg Med Chem Lett; 1999 Jun; 9(12):1691-6. PubMed ID: 10397503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.
    Hanessian S; Moitessier N; Gauchet C; Viau M
    J Med Chem; 2001 Sep; 44(19):3066-73. PubMed ID: 11543675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.
    Fei X; Zheng QH; Liu X; Wang JQ; Sun HB; Mock BH; Stone KL; Miller KD; Sledge GW; Hutchins GD
    Bioorg Med Chem Lett; 2003 Jul; 13(13):2217-22. PubMed ID: 12798337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs on the horizon: matrix metalloproteinase inhibitors.
    Rothenberg ML; Nelson AR; Hande KR
    Stem Cells; 1999; 17(4):237-40. PubMed ID: 10437989
    [No Abstract]   [Full Text] [Related]  

  • 8. Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.
    Hanessian S; MacKay DB; Moitessier N
    J Med Chem; 2001 Sep; 44(19):3074-82. PubMed ID: 11543676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological evaluation of matrix metalloproteinase inhibitors, 18 May 1995, New York.
    Pratta MA
    Inflamm Res; 1995 Nov; 44(11):458-60. PubMed ID: 8597877
    [No Abstract]   [Full Text] [Related]  

  • 10. Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.
    Xue CB; He X; Roderick J; DeGrado WF; Cherney RJ; Hardman KD; Nelson DJ; Copeland RA; Jaffee BD; Decicco CP
    J Med Chem; 1998 May; 41(11):1745-8. PubMed ID: 9599225
    [No Abstract]   [Full Text] [Related]  

  • 11. First insight into structure-activity relationships of selective meprin β inhibitors.
    Ramsbeck D; Hamann A; Schlenzig D; Schilling S; Buchholz M
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2428-2431. PubMed ID: 28408220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.
    Levin JI; Gu Y; Nelson FC; Zask A; DiJoseph JF; Sharr MA; Sung A; Jin G; Cowling R; Chanda P; Cosmi S; Hsiao CL; Edris W; Wilhelm J; Killar LM; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Jan; 11(2):239-42. PubMed ID: 11206468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
    Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
    J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.
    Levin JI; DiJoseph JF; Killar LM; Sharr MA; Skotnicki JS; Patel DV; Xiao XY; Shi L; Navre M; Campbell DA
    Bioorg Med Chem Lett; 1998 May; 8(10):1163-8. PubMed ID: 9871728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel inhibitors of procollagen C-proteinase. Part 2: glutamic acid hydroxamates.
    Robinson LA; Wilson DM; Delaet NG; Bradley EK; Dankwardt SM; Campbell JA; Martin RL; Van Wart HE; Walker KA; Sullivan RW
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2381-4. PubMed ID: 12824039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.
    Duan JJ; Lu Z; Wasserman ZR; Liu RQ; Covington MB; Decicco CP
    Bioorg Med Chem Lett; 2005 Jun; 15(12):2970-3. PubMed ID: 15908214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.
    Campbell DA; Xiao XY; Harris D; Ida S; Mortezaei R; Ngu K; Shi L; Tien D; Wang Y; Navre M; Patel DV; Sharr MA; DiJoseph JF; Killar LM; Leone CL; Levin JI; Skotnicki JS
    Bioorg Med Chem Lett; 1998 May; 8(10):1157-62. PubMed ID: 9871727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral administration of a matrix metalloproteinase inhibitor, CGS 27023A, protects the cartilage proteoglycan matrix in a partial meniscectomy model of osteoarthritis in rabbits.
    O'Byrne EM; Parker DT; Roberts ED; Goldberg RL; MacPherson LJ; Blancuzzi V; Wilson D; Singh HN; Ludewig R; Ganu VS
    Inflamm Res; 1995 Aug; 44 Suppl 2():S117-8. PubMed ID: 8548356
    [No Abstract]   [Full Text] [Related]  

  • 19. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
    Levin JI; Du MT
    Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
    Aranapakam V; Grosu GT; Davis JM; Hu B; Ellingboe J; Baker JL; Skotnicki JS; Zask A; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R
    J Med Chem; 2003 Jun; 46(12):2361-75. PubMed ID: 12773041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.